Section 1: The Strategic Calculus of a Paragraph IV Challenge The decision to initiate a Paragraph IV (Para IV) challenge […]

The pharmaceutical industry is entering a historic super-cycle of patent expirations between 2025 and 2030.1 During this window, an estimated

The Race Nobody Wins Every year, dozens of generic manufacturers file ANDAs for the same thirty drugs. They spend millions

The Forecast That Keeps Getting Wrong Every year, Wall Street analysts publish revenue forecasts for major pharmaceutical products that prove

The most profitable single legal filing in American commerce is not an M&A deal, a securities offering, or a licensing

A deep-dive guide for investors, analysts, and executives who need to anticipate — not react to — patent expirations that

Introduction: Beyond Legal Formalities — Patents as the Cornerstone of Commercial Strategy A single, well-crafted drug patent strategy can be

Arbitraging the Patent Cliff: Using Litigation Dockets to Forecast Generic Entry Pharmaceutical patent litigation determines the timing of billions of

The Question That Makes Regulators Uncomfortable The FDA approves drugs that can kill or cure hundreds of millions of people.